R
Robert J. Amato
Researcher at Baylor College of Medicine
Publications - 80
Citations - 5174
Robert J. Amato is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Chemotherapy & Germ cell tumors. The author has an hindex of 34, co-authored 80 publications receiving 5048 citations. Previous affiliations of Robert J. Amato include Houston Methodist Hospital & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal Article
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
Graham M. Mead,S. P. Stenning,P. A. Cook,Sophie D. Fosså,Alan Horwich,Stan B. Kaye,R.T.D. Oliver,Phm deMulder,R deWit,Gerrit Stoter,Richard Sylvester,Dean F. Bajorin,George J. Bosl,M Mazumdar,Craig R. Nichols,Robert J. Amato,Giorgio Pizzocaro,Jean-Pierre Droz,Andrew Kramar,Gedske Daugaard,H. Cortes-Funes,Luis Paz-Ares,John A. Levi,B. M. Colls,V J Harvey,C Coppin +25 more
TL;DR: An easily applicable, clinically based, prognostic classification for GCT has been agreed on between all the major clinical trial groups who are presently active worldwide and should be used in clinical practice and in the design and reporting of clinical trials to aid international collaboration and understanding.
Journal ArticleDOI
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
Christopher J. Logothetis,Francisco H. Dexeus,Laury Finn,Avishay Sella,Robert J. Amato,Alberto G. Ayala,Robert G. Kilbourn +6 more
TL;DR: It is concluded that MVAC chemotherapy is superior to CISCA chemotherapy, achieving a higher response rate and a longer survival for equivalent patients with metastatic urothelial tumors.
Journal ArticleDOI
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.
Shi Ming Tu,Randall E. Millikan,Bayabel Mengistu,Ebrahim S. Delpassand,Robert J. Amato,Lance C. Pagliaro,Danai D. Daliani,Christos N. Papandreou,Terry L. Smith,Jeri Kim,Donald A. Podoloff,Christopher J. Logothetis +11 more
TL;DR: Bone-targeted consolidation therapy consisting of one dose of Sr-89 plus doxorubicin once a week for 6 weeks, when given to patients with stable or responding advanced androgen-independent carcinoma of the prostate after induction chemotherapy, improved overall survival.
Journal ArticleDOI
Heat shock proteins: the ‘Swiss Army Knife’ vaccines against cancers and infectious agents
TL;DR: The ability of heat shock proteins to interact with antigen presenting cells through a receptor; stimulate antigen presented cells to secrete inflammatory cytokines; and mediate maturation of dendritic cells makes them a one-stop shop for the immune system.
Journal ArticleDOI
Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.
Robert J. Motzer,Robert J. Amato,Robert J. Amato,Mary B. Todd,Wen Jen Poo Hwu,Wen Jen Poo Hwu,Roger B. Cohen,Roger B. Cohen,José Baselga,Hyman B. Muss,Michael A. Cooper,Michael A. Cooper,Richard Yu,Michelle S. Ginsberg,Michael N. Needle +14 more
TL;DR: The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.